- In patients with chronic kidney disease, those with more advanced disease had higher blood levels of the bacterial metabolite phenylacetylglutamine.
- Patients with high phenylacetylglutamine had an elevated risk of developing cardiovascular disease as well as a heightened risk of dying prematurely.
- An estimated 10% of the population worldwide is affected by chronic kidney disease.
Washington, DC (May 26, 2016) -- In patients with chronic kidney disease (CKD), the accumulation of a gut bacterial metabolite that's normally excreted in urine may contribute to serious health problems. The findings come from a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Chronic kidney disease is associated with a heightened risk of premature death and cardiovascular disease. The accumulation of certain factors that are normally excreted by the healthy kidney likely play a role in this elevated risk. More specifically, metabolites generated by gut bacteria are prime candidates due to their toxic nature and the body's dependence on the kidney for their excretion.
A team led by Björn Meijers, MD PhD and Ruben Poesen, MD (University Hospitals Leuven, in Belgium) studied one such metabolite, called phenylacetylglutamine (PAG), in 488 patients with CKD. After following the patients for an average of 3.5 years, the researchers found that blood levels of PAG were higher in patients with more advanced CKD. In addition, patients with high PAG had an elevated risk of developing cardiovascular disease as well as a heightened risk of dying during follow-up.
"There has been increasing awareness that the gut microbiota is not only pivotal for human health but is also involved in various disease processes, including obesity and diabetes mellitus," said Dr. Meijers. "This study adds evidence that the gut microbiota may likewise be a contributor to the disease burden in patients with a diminished kidney function. Furthermore, this knowledge may pave the way for novel therapeutic interventions by both dietary measures and drugs, thereby hopefully improving the prognosis and quality of life of kidney disease patients." Additional studies are needed to uncover the mechanisms underlying the potential toxic nature of these microbial metabolites and to determine whether reducing them may improve patients' health.
Study co-authors include Kathleen Claes, MD, PhD, Pieter Evenepoel, MD, PhD, Henriette de Loor, MSc, Patrick Augustijns, PharmD PhD, Dirk Kuypers, MD, PhD.
Disclosures: Dr. Poesen is the recipient of a PhD fellowship of the Research Foundation - Flanders (FWO). Part of the research has also been funded by FWO.
The article, entitled "Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD," will appear online at http://jasn.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with nearly 16,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.